Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$105.18 USD
+0.09 (0.09%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $105.04 -0.14 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRNA 105.18 +0.09(0.09%)
Will VRNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Other News for VRNA
ClearBridge Small Cap Fund Q2 2025 Commentary
PERCEPTIVE ADVISORS LLC Increases Stake in Praxis Precision Medicines Inc
ClearBridge Small Cap Strategy Q2 2025 Commentary
TimesSquare U.S. Small Cap Growth Strategy Q2 2025 Commentary
Is the Market Bullish or Bearish on Verona Pharma?